Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness
The ESCAPE Trial

The ESCAPE Investigators and ESCAPE Study Coordinators *

A dvances in medical therapy have improved outcomes for many ambulatory patients with heart failure and low ejection fraction (EF).1-4 However, each year an estimated 250 000 to 300 000 patients are hospitalized for heart failure with low EF;3 and the 1-year survival rate after hospitalization may be as low as 50%, even with recommended medical therapies.6,7

In nonrandomized studies, patients undergoing therapy with vasodilators and diuretics to reduce filling pressures to near normal levels have had acute and sustained improvements in hemodynamics, mitral regurgitation, and exercise tolerance.8-15 Without a randomized study of hemodynamic monitoring with the pulmonary artery catheter (PAC), however, it could not be determined whether PACs improved outcomes in addition to other components of intensive heart failure management.

There is considerable controversy over use of the PAC in critical illness. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) trial demonstrated higher mortality for patients thought to require PAC during hospitalization, although without excess risk for patients with heart failure.16 Reports from acute myocardial infarc-

Context Pulmonary artery catheters (PACs) have been used to guide therapy in multiple settings, but recent studies have raised concerns that PACs may lead to increased mortality in hospitalized patients.

Objective To determine whether PAC use is safe and improves clinical outcomes in patients hospitalized with severe symptomatic and recurrent heart failure.

Design, Setting, and Participants The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) was a randomized controlled trial of 433 patients at 26 sites conducted from January 18, 2000, to November 17, 2003. Patients were assigned to receive therapy guided by clinical assessment and a PAC or clinical assessment alone. The target in both groups was resolution of clinical congestion, with additional PAC targets of a pulmonary capillary wedge pressure of 15 mm Hg and a right atrial pressure of 8 mm Hg. Medications were not specified, but inotrope use was explicitly discouraged.

Main Outcome Measures The primary end point was days alive out of the hospital during the first 6 months, with secondary end points of exercise, quality of life, biochemical, and echocardiographic changes.

Results Severity of illness was reflected by the following values: average left ventricular ejection fraction, 19%; systolic blood pressure, 106 mm Hg; sodium level, 137 mEq/L; urea nitrogen, 35 mg/dL (12.40 mmol/L); and creatinine, 1.5 mg/dL (132.6 µmol/L). Therapy in both groups led to substantial reduction in symptoms, jugular venous pressure, and edema. Use of the PAC did not significantly affect the primary end point of days alive and out of the hospital during the first 6 months (133 days vs 135 days; hazard ratio [HR], 1.00 [95% confidence interval {CI}, 0.82-1.21]; P = .99), mortality (43 patients [10%] vs 38 patients [9%]; odds ratio [OR], 1.26 [95% CI, 0.78-2.03]; P = .35), or the number of days hospitalized (8.7 vs 8.3; HR, 1.04 [95% CI, 0.86-1.27]; P = .67). In-hospital adverse events were more common among patients in the PAC group (47 [21.9%] vs 25 [11.5%]; P = .04). There were no deaths related to PAC use, and no difference for in-hospital plus 30-day mortality (10 [4.7%] vs 11 [5.0%]; OR, 0.97 [95% CI, 0.38-2.22]; P = .97). Exercise and quality of life end points improved in both groups with a trend toward greater improvement with the PAC, which reached significance for the time trade-off at all time points after randomization.

Conclusions Therapy to reduce volume overload during hospitalization for heart failure led to marked improvement in signs and symptoms of elevated filling pressures with or without the PAC. Addition of the PAC to careful clinical assessment increased anticipated adverse events, but did not affect overall mortality and hospitalization. Future trials should test noninvasive assessments with specific treatment strategies that could be used to better tailor therapy for both survival time and survival quality as valued by patients.

©2005 American Medical Association. All rights reserved.

See also pp 1664 and 1693.

*Authors are listed at the end of this article.

Corresponding Author: Lynne W. Stevenson, MD, Brigham and Women’s Hospital, Cardiovascular Division, Department of Medicine, 75 Francis St, PB8-1, Boston, MA 02115 (lstevenson@partners.org).

JAMA. 2005;294:1625-1633  www.jama.com
tion populations further raised concerns that PACs increased mortality, and a moratorium on PAC use was proposed. Recommendations from a working group of representatives from the National Heart, Lung, and Blood Institute (NHLBI), the Food and Drug Administration, and academic experts in cardiology, pulmonology, surgery, nursing, and critical care led to a trial designed to test the PAC in patients with chronic heart failure.18

The complexity of this population and the challenge of hemodynamic measurement made experience in hemodynamic studies desirable. However, refinement of clinical assessment based on prior hemodynamic investigation could diminish the impact of PAC information. Recognizing this conflict, the decision was made to test the PAC with experienced heart failure investigators. For the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), the primary hypothesis was that for patients with severe heart failure, therapy guided by PAC monitoring and clinical assessment would lead to more days alive and fewer days hospitalized during 6 months compared with therapy guided by clinical assessment alone.

METHODS

Trial Organization
ESCAPE was an NHLBI-sponsored randomized trial conducted at 26 experienced heart failure centers in the United States and Canada. The Brigham and Women’s Hospital served as the clinical coordinating center, and Duke Clinical Research Institute was the data coordinating center and performed all statistical analyses. The NHLBI appointed an independent data and safety monitoring board. Participating institutional review boards approved the protocol, and written informed consent was obtained from all patients.

Patients
Inclusion criteria were designed to select patients with severe symptomatic heart failure despite recommended therapies.18 The target patient was sufficiently ill with advanced heart failure to make use of the PAC reasonable, but also sufficiently stable to make crossover to PAC for urgent management unlikely. Severity prior to admission could be met by the following criteria: (1) hospitalization for heart failure within the past year; (2) urgent visit to the emergency department; or (3) treatment during the preceding month with more than 160 mg of furosemide daily (or equivalent). Randomization required at least 3 months of symptoms despite angiotensin-converting enzyme (ACE) inhibitors and diuretics, left ventricular (LV) EF 30% or less, systolic blood pressure 125 mm Hg or less, and at least 1 sign and 1 symptom of congestion. Exclusion criteria to minimize confounding comorbidities or urgent crossover included creatinine level greater than 3.5 mg/dL (309.4 µmol/L), or prior use of dobutamine or dopamine more than 3 µg/kg/min, or any prior use of milrinone during the current hospitalization. Right heart catheterization to assess pulmonary hypertension during transplant evaluation was permitted in patients receiving therapy guided by clinical assessment alone if performed at the end of hospitalization.

A concurrent PAC registry was established to characterize hospitalized patients receiving PACs considered to be required during heart failure management.

Study Design and Analyses
Patients were randomly assigned 1:1 to therapy guided by clinical assessment only (clinical assessment group) or therapy guided by clinical assessment and the PAC (PAC group). Randomization was stratified by site using random block sizes of 2 or 4 through a central telephone center. The treatment goal in the clinical assessment group was resolution of clinical signs and symptoms of congestion, particularly jugular venous pressure elevation, edema, and orthopnea. Treatment goals in the PAC group were the same, with the addition of pulmonary capillary wedge pressure (PCWP) of 15 mm Hg and right atrial pressure of 8 mm Hg. Therapy was adjusted in both groups to avoid progressive renal dysfunction or symptomatic systemic hypotension.

The protocol did not specify drug selection or dosing. Investigators were encouraged to follow national guidelines for treatment of heart failure and to primarily use intravenous diuretics and vasodilators. The use of inotropic agents for routine management was consistently and explicitly discouraged. No specific instructions were given regarding nesiritide, which became available during the course of the trial.

The Pulmonary Artery Catheter Education Project, a computer-based program created by the NHLBI, the Food and Drug Administration, and the American College of Physicians, was used at study initiation to train investigators and coordinators (http://www.pacep.org/asahq). Catheters were selected according to individual institutional practice. In the PAC group, hemodynamics were measured twice at baseline and at least twice daily thereafter, with pressure measurement from paper readings. A specific case report form listed anticipated PAC complications.

Patients were seen at 7 to 14 days, and 1, 2, 3, and 6 months after discharge. Data were collected on clinical status, medications, exercise, and quality of life measurements. Race and ethnicity were assessed by the study coordinator from patients and chart information to determine degree of diverse representation in the study population. The primary end point, days alive out of the hospital during 6 months following randomization, was analyzed using the Cox proportional hazards model. Component end points included time to events. End points were calculated with patients receiving transplant or assist devices coded as dead, then recalculated coded as alive.

Because patients and physicians were not blinded to treatment, physiologic secondary end points, focusing on mitral regurgitation (the subject of pending analysis), natriuretic peptides, and peak oxygen consumption, were se-
lected as measurable without knowledge of group assignment. Other functional end points were 6-minute walk distance,19 the Minnesota Living with Heart Failure questionnaire,20 and the time trade-off tool,21 which quantifies how many months of life out of 24 months patients would trade to feel better, through a series of binary questions asked by a trained coordinator, as has been described for moderate-severe heart failure. All baseline functional measures were made before randomization. A new end point of time trade-off–adjusted survival was prospectively defined for exploratory analysis as the integrated product of the days alive and the proportion of months preferred in current health at each time point.

The original design included 500 randomized patients, based on the assumption that the control group would have an expected 40 days dead or hospitalized with an SD of 30. The treated group was assumed to have an expected number of days of 32 (0.8×40). This resulted in an estimated power of 84%, assuming normality of days hospitalized (assuming a 2-sided test at an α level of .05). Interim unblinded analyses for efficacy occurred after 19%, 46%, 59%, and 67% of the patients had been enrolled. Approximate O’Brien-Fleming boundaries were used based on the group-sequential methods of Lan et al.22 No provision was made for stopping early for futility. None of the tests were close to the stopping boundaries.

The secondary end points, including exercise, natriuretic peptides, and quality of life, were analyzed with the t test using SAS version 8.2 (SAS Institute Inc, Cary, NC) with an α level of .05. All analyses were based on intention to treat.

RESULTS

Baseline Characteristics

From January 18, 2000, to November 17, 2003, 433 patients were enrolled (Figure 1). The data and safety monitoring board recommended that the NHLBI stop the trial before enrolling 500 patients due to concerns of early adverse events and the unlikelihood of achieving a significant difference in the primary end point.

The 2 randomized groups had similar baseline characteristics (Table 1), with 391 (90%) taking ACE inhibitors or angiotensin-receptor blockers, 268 (62%) taking β-blockers, and 31 (7%) with implantable defibrillators. During the same time, patients receiving the PAC without randomization (PAC registry) had higher LVEF, but more compromise of blood pressure, serum sodium and creatinine levels, and inotropic therapy (35% vs 15%).

Treatment After Randomization

Intravenous diuretics were used in all patients. Vasodilator therapy was used in 80 (37%) patients in the PAC group and 42 patients (19%) in the clinical assessment group (total nesiritide, 66 [15%]; nitroprusside, 50 [12%]; nitroglycerin, 16 [4%]). Inotropic therapy was used in 94 (44%) patients in the PAC group and 86 patients (39%) in the clinical assessment group. Discharge prescriptions included ACE inhibitors/angiotensin-receptor blockers for 196 (91%) patients in the PAC group and 195 patients (89%) in the clinical assessment group, and β-blockers for 140 (65%) patients in the PAC group and 128 patients (59%) in the clinical assessment group.

PACs were placed for adjustment of therapy in 198 (92%) patients in the PAC group and 21 patients (10%) in the clinical assessment group during hospitalization. PACs in patients in the treatment group were in place for a median of 1.9 days, during which all hemodynamic parameters improved (Table 2). Substantial impact of therapy on clinical goals by the time of discharge was similar in both groups (Table 3). Although average weight loss was 3.2 kg for patients in the clinical assessment group vs 4.0 kg for patients in the PAC group, serum creatinine level worsened less often in the PAC group.

Primary End Point

Use of the PAC did not affect the primary end point of days alive out of the hospital (Figure 2). The overall neutrality of the intervention was consistent across demographic subgroups (Figure 3). There were no significant differences in time to death or hospitalization, deaths, or days hospitalized (Table 4). Both groups had a median of 2.0 hospitalizations per patient. Coding the 36 patients who underwent cardiac transplantation or LV assist device placement as either dead or alive did not change the results.

There were no clinical subgroups in which benefit or harm was shown. There was a trend for better PAC outcomes in the centers with higher volume enrollment. There was no evidence of benefit or harm from the PAC in relation to intravenous vasoactive therapy (Table 5).

Safety of the PAC

Adverse events specifically attributed to PACs occurred in 9 patients in the PAC group and 1 patient in the clinical assessment group later receiving a PAC.
These specific events were PAC-related infection (4 patients), bleeding (2 patients), catheter knotting (2 patients), pulmonary infarction/hemorrhage (2 patients), and ventricular tachycardia (1 patient). There were no hospital deaths attributed to the PAC. Adverse events, most commonly infection, occurred in-hospital almost twice as often in the PAC patients, but occurred in 143 patients in each group over 6 months. Other cardiac procedures occurred in 81 (38%) patients in the PAC group and 89 (41%) in the clinical assessment group during hospitalization.

Secondary End Points

Natriuretic peptides decreased similarly in both groups. Functional end points improved significantly during hospitalization in both groups, with a trend for more improvement in the PAC group (Figure 4). The Minnesota Living with Heart Failure questionnaire improved in both groups by 1 month, with greater improvement in the PAC group. By 6 months, scores in the clinical assessment group had improved to match the PAC group.

The time trade-off showed greater improvement for the PAC group compared with the clinical assessment group at all time points (1, 2, 3, and 6 months; \( P = .001-.02 \)). By the end of the study, the average improvement (decrease in survival months to be traded for better health) was 6.2 months in the PAC group compared with 0.9 months in the clinical assessment group. Benefit remained if LV assist device or transplant patients were given the worst score (\( P = .03-.05 \)). When the missing data were modeled using the newly described method of Davidian et al, the results were no longer significant, but the effects trended in the same direction. The exploratory secondary end point of direct time trade-off–adjusted

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PAC Group (n = 215)</th>
<th>Clinical Assessment Group (n = 218)</th>
<th>( P ) Value, Clinical Assessment vs PAC*</th>
<th>PAC Registry (n = 439)</th>
<th>( P ) Value, Randomized vs Registry†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>56 (14)</td>
<td>56 (14)</td>
<td>.82</td>
<td>59 (14)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Male, %</td>
<td>74</td>
<td>74</td>
<td>.93</td>
<td>69</td>
<td>.06</td>
</tr>
<tr>
<td>Race, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>124 (58)</td>
<td>134 (62)</td>
<td>.42</td>
<td>348 (81)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Minority</td>
<td>91 (42)</td>
<td>84 (39)</td>
<td></td>
<td>80 (19)</td>
<td></td>
</tr>
<tr>
<td>Etiology, No. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ischemic</td>
<td>110 (51)</td>
<td>105 (49)</td>
<td>.60</td>
<td>240 (55)</td>
<td>.16</td>
</tr>
<tr>
<td>Nonischemic</td>
<td>105 (49)</td>
<td>113 (51)</td>
<td></td>
<td>199 (45)</td>
<td></td>
</tr>
<tr>
<td>Heart rate, mean (SD), beats/min</td>
<td>83 (15)</td>
<td>82 (16)</td>
<td>.70</td>
<td>84 (18)</td>
<td>.67</td>
</tr>
<tr>
<td>Ejection fraction, mean (SD), %</td>
<td>19 (7)</td>
<td>20 (6)</td>
<td>.53</td>
<td>24 (14)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Systolic blood pressure, mean (SD), mm Hg</td>
<td>106 (17)</td>
<td>106 (15)</td>
<td>.77</td>
<td>104 (21)</td>
<td>.008</td>
</tr>
<tr>
<td>Sodium, mean (SD), mEq/L</td>
<td>137 (4.4)</td>
<td>137 (4.4)</td>
<td>.66</td>
<td>135 (5.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Urea nitrogen, mean (SD), mg/dL</td>
<td>94 (21)</td>
<td>94 (24)</td>
<td>.88</td>
<td>92 (30)</td>
<td>.004</td>
</tr>
<tr>
<td>Creatinine, mean (SD), mg/dl</td>
<td>1.5 (0.6)</td>
<td>1.5 (0.6)</td>
<td>.50</td>
<td>2.0 (1.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Baseline BNP, mean (SD), pg/mmol</td>
<td>974 (1216)</td>
<td>1018 (1400)</td>
<td>.96</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Peak VO(_2), mean (SD)</td>
<td>10.2 (3.9)</td>
<td>9.9 (2.9)</td>
<td>.90</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>6-min walk, mean (SD), ft</td>
<td>390 (400)</td>
<td>437 (431)</td>
<td>.37</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Baseline MLHF score, mean (SD)</td>
<td>74 (17)</td>
<td>73 (18)</td>
<td>.60</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: BNP, brain natriuretic peptide; ESCAPE, Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; MLHF, Minnesota Living with Heart Failure; NA, not applicable; VO\(_2\), peak oxygen consumption.

*\( P \) value for comparison between PAC and clinical assessment groups.
†\( P \) value for comparison between ESCAPE trial and PAC registry.

**Table 1.** Baseline Characteristics of Randomized Patients and Patients Receiving Pulmonary Artery Catheterization (PAC) Without Randomization in ESCAPE Trial

\( SI \) conversion factors: To convert urea nitrogen to mmol/L, multiply by 0.357; creatinine to µmol/L, multiply by 88.4.

**Table 2.** Impact of Therapy Guided by Pulmonary Artery Catheterization During the Course of Hospitalization

<table>
<thead>
<tr>
<th>Hemodynamic Measurement</th>
<th>Baseline</th>
<th>Final†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right atrial pressure, mm Hg</td>
<td>14 (10)</td>
<td>10 (7)</td>
</tr>
<tr>
<td>Pulmonary capillary wedge pressure, mm Hg</td>
<td>25 (9)</td>
<td>17 (7)</td>
</tr>
<tr>
<td>Cardiac index, L/min/mm(^2)</td>
<td>1.9 (0.6)</td>
<td>2.4 (0.7)</td>
</tr>
<tr>
<td>Cardiac output, L/min</td>
<td>3.8 (1.2)</td>
<td>4.8 (2.1)</td>
</tr>
<tr>
<td>Systemic vascular resistance, dynes ( \times ) cm(^{-5}) sec(^{-1})</td>
<td>1500 (800)</td>
<td>1100 (500)</td>
</tr>
</tbody>
</table>

*Data are expressed as mean (SD).
†\( P < .001 \) for all variables. The final hemodynamics are those measured just before removal of the pulmonary artery catheter, which occurred at a median of 1.9 days after insertion.
Table 3. Impact of Interventions on Discharge Status

<table>
<thead>
<tr>
<th></th>
<th>PAC Group (n = 219)</th>
<th></th>
<th>Clinical Assessment Group (n = 218)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>Discharge</td>
<td>Mean Change</td>
<td>Baseline</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>85.7 (21.8)</td>
<td>80.8 (20.3)</td>
<td>-4.0 (5.4)</td>
<td>85.6 (20.3)</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>106 (17)</td>
<td>102 (15)</td>
<td>-4 (17)</td>
<td>106 (15)</td>
</tr>
<tr>
<td>Estimated jugular venous pressure, mm Hg</td>
<td>12.1</td>
<td>6.7</td>
<td>45%</td>
<td>12.5</td>
</tr>
<tr>
<td>Edema§</td>
<td>134 (67)</td>
<td>41 (20)</td>
<td>-93 (46)</td>
<td>139 (68)</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>1.5 (0.6)</td>
<td>1.5 (0.6)</td>
<td>0.0 (0.4)</td>
<td>1.5 (0.6)</td>
</tr>
<tr>
<td>Urea nitrogen, mg/dL</td>
<td>34 (21)</td>
<td>37 (21)</td>
<td>2 (18)</td>
<td>36 (24)</td>
</tr>
<tr>
<td>Sodium, mEq/L</td>
<td>136.5 (4.4)</td>
<td>135.2 (3.9)</td>
<td>-1.3 (3.9)</td>
<td>136.7 (4.4)</td>
</tr>
<tr>
<td>Symptom score (global)</td>
<td>43 (22)</td>
<td>68 (20)</td>
<td>25 (25)</td>
<td>41 (21)</td>
</tr>
<tr>
<td>Orthopnea (0-4 scale)</td>
<td>3.3 (1.1)</td>
<td>1.9 (1.0)</td>
<td>-1.4 (1.2)</td>
<td>3.4 (1.0)</td>
</tr>
</tbody>
</table>

Abbreviation: PAC, pulmonary artery catheter.
SI conversion factors: To convert creatinine to μmol/L, multiply by 88.4; urea nitrogen to mmol/L, multiply by 0.357.
*Data are expressed as mean (SD) unless otherwise indicated.
†Significant (P<.05) change from baseline to discharge.
§Edema refers to the number of patients with edema; change indicates the fraction improving from baseline to discharge.
|                      | Baseline | Discharge | Mean Change | Baseline | Discharge | Mean Change |
|----------------------|------------------|------------------------------------|------------------|------------------------------------|------------------|

Neutral Impact of PAC on Primary End Point

The absence of benefit for the PAC on the primary end point could have resulted from multiple factors listed below, as anticipated in the original design.18

Safety

Previous retrospective studies raised the possibility that the catheter itself was associated with sufficient adverse events to influence major outcomes.20,24,25 The PAC, as used by the investigating sites in ESCAPE, appeared overall to be safe. The results suggest that retrospective reports of excess mortality with PACs were confounded by the severity of clinical status leading to the decision to use PACs. This is supported by the more severe clinical compromise in PAC registry patients in this study (Table 1). In ESCAPE there were only 9 (4.2%) direct procedural complications, which may reflect both experienced sites and specific education prior to site enrollment.

Impact of Therapy to Reduce Filling Pressures

In the PAC group, therapy tailored to approach a PCWP of 15 mm Hg and a right atrial pressure of 8 mm Hg reduced these pressures effectively. Marked clinical resolution of the signs and symptoms of congestion occurred in both groups (Table 3), providing a benchmark for the effectiveness of therapy during hospitalization for heart failure. The accuracy of skilled investigators in clinical assessment of filling pressures may have been adequate to identify and monitor the clinical interventions required without precise hemodynamic confirmation.

The prognostic importance of achieving low PCWP at discharge has been previously described.26-28 The relation between filling pressures and mortality likely reflects multiple interactions with disease progression.29,31 As in prior experiences, it is not possible to determine whether achievement of lower filling pressures actually caused better outcomes or merely identified patients with more favorable outcomes regardless of therapy.

Choice of Therapies

Benefit derived from the PAC might have been offset if knowing hemodynamic information triggered excess use of medications with deleterious consequences. Such differences appeared to

©2005 American Medical Association. All rights reserved.
The hazard ratio for the primary end point of days neither dead nor hospitalized is provided for subgroups based on prerandomization characteristics. A clinical estimate of whether the cardiac index was above or below 2.2 L/min/m² was part of the information required from the investigator prior to randomization. The centers were divided into the high and low enrolling sites based on the number of patients randomized. Complete data on mortality and rehospitalization were available for 413 patients who were used for analysis of the primary end point.

*Three patients did not have a clinical estimate of cardiac index recorded at the time of randomization.

### Table 4. Primary Outcomes: Mortality and Hospitalizations

<table>
<thead>
<tr>
<th>Measure</th>
<th>PAC Group</th>
<th>Clinical Assessment Group</th>
<th>End Point Estimate (95% CI)</th>
<th>( \chi^2 )</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days alive out of hospital, mean</td>
<td>133</td>
<td>135</td>
<td>Hazard ratio, 1.00 (0.82-1.21)</td>
<td>0.00</td>
<td>.99</td>
</tr>
<tr>
<td>LVADs/transplants coded dead</td>
<td>141</td>
<td>143</td>
<td>Hazard ratio, 0.99 (0.82-1.21)</td>
<td>0.00</td>
<td>.95</td>
</tr>
<tr>
<td>LVADs/transplants coded well</td>
<td>43</td>
<td>38</td>
<td>Odds ratio, 1.26 (0.78-2.03)</td>
<td>0.86</td>
<td>.35</td>
</tr>
<tr>
<td>Mortality (dead at 180 d), No.</td>
<td>8.7</td>
<td>8.3</td>
<td>Hazard ratio, 1.04 (0.86-1.27)</td>
<td>0.18</td>
<td>.67</td>
</tr>
<tr>
<td>Total days initial hospitalization, mean</td>
<td>0.97</td>
<td>0.97</td>
<td>NA</td>
<td>.04</td>
<td>.97</td>
</tr>
<tr>
<td>PAC-related deaths, No.</td>
<td>0</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Early deaths (in-hospital plus 30 d), No.</td>
<td>10</td>
<td>11</td>
<td>Odds ratio, 0.97 (0.38-2.22)</td>
<td>.04</td>
<td>.97</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; LVAD, left ventricular assist device; NA, not applicable; PAC, pulmonary artery catheter.

*Values less than 1 favor PAC.

### Table 5. Primary End Point Results by Inotrope and Vasodilator Use After Randomization

<table>
<thead>
<tr>
<th>Group</th>
<th>PAC Group</th>
<th>Clinical Assessment Group</th>
<th>End Point Hazard Ratio (95% CI)</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inotrope (n = 180)</td>
<td>72</td>
<td>73</td>
<td>0.93 (0.69-1.27)</td>
<td>.66</td>
</tr>
<tr>
<td>No inotrope (n = 253)</td>
<td>62</td>
<td>60</td>
<td>1.00 (0.78-1.29)</td>
<td>.97</td>
</tr>
<tr>
<td>Vasodilator without inotrope (n = 75)</td>
<td>66</td>
<td>57</td>
<td>0.99 (0.60-1.64)</td>
<td>.98</td>
</tr>
<tr>
<td>Neither inotrope or vasodilator (n = 178)</td>
<td>59</td>
<td>61</td>
<td>0.93 (0.68-1.27)</td>
<td>.63</td>
</tr>
</tbody>
</table>

Abbreviation: CI, confidence interval.

*Event rates are compared between PAC group and clinical assessment group for the 4 drug treatment groups. Event rates for the 4 groups by drug treatment are not compared, as the inotrope and vasodilator therapies were not selected by randomization.

Comparison With Previous Results in Advanced Heart Failure

There have been no previous randomized trials of therapy tailored during continuous hemodynamic monitoring in heart failure. Use of an indwelling PAC to adjust therapy in advanced heart failure was first described by Kovick et al and subsequently by Pierpont for vasodilator therapy in decompensated heart failure with high systemic vascular resistance. It became common to assess reversibility of secondary pulmonary hypertension during transplant evaluation, for which reduction of LV filling pressures is crucial. The approach of tailoring therapy to reduce filling pressures was then extended to improve clinical status for patients awaiting or ineligible for transplantation. This approach, combined with intensive outpatient heart failure management, was associated with reduced hospitalizations, decreased clinical congestion, and improved exercise capacity. Similar experiences elsewhere demonstrated recognition of clinically unappreciated volume overload and improved exercise capacity when therapy was adjusted using PAC information.

The advanced heart failure population and therapies have evolved since these experiences. Decompensation was previously accompanied by severe vasoconstriction, such that aggressive vasodilation in addition to diuresis was required to reduce filling pressures. Patients now have longer duration of heart failure and ACE inhibitor use prior to advanced symptoms, and many have
received β-blockers. The average systemic vascular resistance at baseline in ESCAPE was only 1500 dynes × s/cm², compared with over 1800 dynes × s/cm² in several previous experiences.15 However, progression of renal dysfunction and diuretic resistance more commonly limits therapy than previously. The average discharge furosemide equivalent was 180 mg, compared with less than 100 mg in earlier experiences. Current therapy during hospitalization for heart failure now may focus less on high filling pressures with vasoconstriction and more on high filling pressures with renal dysfunction.

There have been 11 previous randomized trials of PACs in critical illness, in which the goals of therapy diverged from those described here for heart failure. A meta-analysis of these trials, including ESCAPE, showed a hazard ratio of 1.00 for mortality and hospitalization. The recently published PAC-Man trial of 1014 patients from varied practice settings in the United Kingdom also demonstrated no effect on major end points in the overall population or in the 11% of patients with heart failure. These trials support the safety of PACs and the overall neutral effect, while highlighting the challenge of assessing a diagnostic tool without a consistent strategy of response with effective therapies.

Secondary Functional End Points
Function and quality of life are crucial to patients with heart failure, a chronic debilitating disease. ESCAPE is distinct from other trials of PAC, which have included patients during acute events with anticipated complete recovery. As revealed in our patients’ preferences, survival is not the only, and for some not the most important, metric of benefit. While improvement in clinical status in both groups was substantial and sustained, a consistent trend suggested greater improvement in patients in whom therapy had been adjusted using PACs. This could reflect the close relation between filling pressures and symptoms of congestion. Exercise capacity has been shown to improve with reduction of filling pressures beyond that needed to treat edema. The heart failure questionnaire improvement was greater by 5 points at 1 month in the PAC group, a level that has been established as clinically meaningful to patients.

The time trade-off tool has only recently been used to assess patients with heart failure. Primarily used in severe illnesses such as cancer, it correlates with functional assessments and symptom scales, but with marked individual variation. Some patients want survival at any cost, while others focus more on improving daily life than prolonging it. The improvement in the PAC group was more than twice as great at every time point, suggesting that the patients awarded more value to their lives after therapy adjusted to lower filling pressures. The time trade-off instrument has shown a strong relation between elevated jugular venous pressure and willingness to trade time for better health quality. In ESCAPE, the average time to be traded out of 24 months was 9 months at the time of randomization, confirming that patients with this severity of illness place high value on improving their quality of life.

Applicability of ESCAPE Results
There were no subgroups identified in which the impact of PAC use was significantly different from the overall trial. The representation of 175 (40%) minority subjects and 112 (26%) women suggests that similar considerations apply to PAC use in these groups. The population was defined specifically to exclude patients in whom PAC insertion seemed likely for urgent management.

ESCAPE centers were specifically selected for experience with clinical and hemodynamic assessment during therapy for advanced heart failure. The ESCAPE benchmark for clinical improvement during hospitalization for heart failure derives from experienced clinicians, recognized to be more accurate with both physical assessment and interpretation of hemodynamic

---

**Table 6. Adverse Events In-hospital**

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>PAC Group (n = 215)</th>
<th>Clinical Assessment Group (n = 218)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implantable cardioverter-defibrillator firing</td>
<td>5 (2.3)</td>
<td>1 (0.5)</td>
<td>.08</td>
</tr>
<tr>
<td>Cardiogenic shock</td>
<td>6 (0.5)</td>
<td>2 (0.9)</td>
<td>.12</td>
</tr>
<tr>
<td>Ischemia/angina</td>
<td>9 (4.2)</td>
<td>4 (1.8)</td>
<td>.13</td>
</tr>
<tr>
<td>PAC infection</td>
<td>4 (1.9)</td>
<td>0 (0.0)</td>
<td>.03</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>0 (0.0)</td>
<td>1 (0.5)</td>
<td>.75</td>
</tr>
<tr>
<td>Stroke or transient ischemic attack</td>
<td>1 (0.5)</td>
<td>0 (0.0)</td>
<td>.75</td>
</tr>
<tr>
<td>Cardiac arrest</td>
<td>9 (4.2)</td>
<td>5 (2.3)</td>
<td>.23</td>
</tr>
<tr>
<td>Infection</td>
<td>27 (12.6)</td>
<td>20 (9.2)</td>
<td>.25</td>
</tr>
<tr>
<td>Patients with at least 1 adverse event</td>
<td>47 (21.9)</td>
<td>25 (11.5)</td>
<td>.04</td>
</tr>
</tbody>
</table>

Abbreviation: PAC, pulmonary artery catheter.

*P values calculated as Fisher exact mid-P values.

**Figure 4. Change in Secondary End Points**

Change in secondary end points is presented as an effect size of the changes in the 2 treatment groups. ANP indicates atrial natriuretic peptide; BNP, brain natriuretic peptide; VO₂, peak oxygen consumption; MLHF, Minnesota Living with Heart Failure questionnaire; and TTO, time trade-off score.
ESCAPE TRIAL OF PULMONARY ARTERY CATHETERIZATION EFFECTIVENESS

measurements. The safety of the PAC procedure also applies only to experienced centers, with a trend for better outcomes in those with the highest enrollment. With the absence of benefit for the primary end point, there is no rationale at this time to increase the number of centers using the PAC for the management of heart failure.

Limitations

Interpretation of the ESCAPE results is limited by the lack of definition of precise strategy in response to the hemodynamic information obtained. There was considerable variation between sites in use of medications. Exercise tests, quality of life questionnaires, and the time trade-off utility assessments were secondary end points, with missing data that could not be assumed to occur randomly. Challenge arises in interpreting positive findings among an array of secondary end points dominated by a neutral primary end point.

Implications for PAC Use in Advanced Heart Failure

Based on ESCAPE, there is no indication for routine use of PACs to adjust therapy during hospitalization for decompensation of chronic heart failure. It seems probable that there are some patients and some therapies that yield improved outcome with PAC monitoring and others with counterbalancing deleterious effects. The ESCAPE trial does not provide information on using PACs in cardiogenic shock or in triage for LV assist devices and cardiac transplantation.

For patients in whom signs and symptoms of congestion do not resolve with initial therapy, consideration of PAC monitoring at experienced sites appears reasonable if the information may guide further choices of therapy. In light of accumulating information regarding the deleterious effect of intravenous inotropic therapy, the PAC might be used to guide therapies for patients in whom inotropic therapy would otherwise be used.

The ESCAPE trial defined the most compromised patient population to be studied in an NHLBI heart failure trial with medical therapy, with 19% (83 patients) mortality at 6 months. No diagnostic test by itself will improve outcomes. New strategies should be developed to test both the interventions and the targets to which they should be tailored. Although most trials in a high-event population have focused on reducing mortality, patients with advanced heart failure express willingness to trade survival time for better health during the time remaining. How patients value their daily lives should help guide both the design and evaluation of new therapies.

Authors: Certifying authors are members of the Executive and Publications committees of the ESCAPE trial. Authors/members of the Executive and Publications committees, study investigators, and coordinating sites are listed below.

Authors Contributions: Dr Stevenson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.


Authors/ESCAPE Executive Committee: Cynthia Binanay, RN, BS, Duke Clinical Research Institute, Durham, NC; Robert M. Califf, MD, Division of Cardiology, Duke University Medical Center; and Duke Clinical Research Institute, Durham, NC; Vincent Hasselblad, PhD, Biotestistics and Bioinformatics, Duke Clinical Research Center, Durham, NC; Christopher M. O’Connor, MD, Division of Cardiology, Duke University Medical Center; and Duke Clinical Research Institute, Durham, NC; Monica R. Shah, MD, MHS, MSJ, Department of Cardiology, Columbia University Medical Center, New York, NY; George Sopko, MD, MPH, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; Lynne W. Stevenson, MD, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.

Authors/ESCAPE Publications Committee: Gary S. Francis, MD, Coronary Intensive Care Unit, The Cleveland Clinic Foundation, Cleveland, Ohio; Carl V. Leier, MD, Division of Cardiovascular Medicine, The Ohio State University, Columbus; Leslie W. Miller, MD, Division of Cardiology, University of Minnesota, Minneapolis.

ESCAPE Site Investigators, Study Coordinators: University of Florida: James A. Hill, MD/Daniel F. Pauly, MD, Debra R. Oltisky; University of Minnesota: Leslie W. Miller, MD, Judith A. Graziano, Mary Ellen Berman; Mayo Clinic: Robert Frantz, MD, Karen Hartman; The Ohio State University: Carl V. Leier, MD/William T. Abraham, MD, Laura Yamokoski; Mass General: Thomas G. Disalvo, MD, Janice Camuso; Northwestern: Mihai Cheighrihsade, MD, Karen Fachet; Rush-Presbyterian: Alain Heroux, MD, Soo Jin Kim; University of California, San Diego: Wayne Warrica, MD, Jane Grant, University of Kentucky: Mian Hasan, MD, Lydia Withrow; The Cleveland Clinic Foundation: James Young, MD, Barbara Gus; Vanderbilt University: Javed Butler, MD, Laurie Hawkins; University of Alabama: Barry K. Rayburn, MD, Jessica Robinson; University Hospitals of Cleveland: Ieana Piha, MD, Lori Shelby; Washington University: Joseph Rogers, MD, Heidi Craddock; Anaheim Heart: Melvin Tonkon, MD, Shane Miller, UCSF: Teresa DeMarco, MD, Debra Lau; University of Wisconsin: Maryl Johnson, MD, Cassondra Vander Ark.

Operations Team: Wanda Tate, BA, Michael Wilson, BSPh, Nevin Hayes, Gudaye Tassia, PhD, Valerie Morrow, MD, and Cynthia Binanay, RN, BSN, Duke Clinical Research Institute, Durham, NC.

Funding Support: This research was supported by contract N01-HV-98177 from the National Heart, Lung, and Blood Institute to Duke University Medical Center.

Role of the Sponsor: The National Heart, Lung, and Blood Institute oversaw the formulation and activities of the data and safety monitoring board. Dr Sopko contributed to the trial design and execution and participated in the analysis of the data and preparation of the manuscript.

REFERENCES


ESCAPE TRIAL OF PULMONARY ARTERY CATHETERIZATION EFFECTIVENESS


©2005 American Medical Association. All rights reserved.
(Reprinted) *JAMA,* October 5, 2005—Vol 294, No. 13-1633